The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from chinese hamster ovary-m1 cells

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT

Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 315,771 · see citing works

Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides

Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · see citing works

Amyloid β-peptide is produced by cultured cells during normal metabolism

Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · see citing works

Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · see citing works

Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing

Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · see citing works

Cleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor

Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,403 · see citing works

Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein

Weidemann, A., König, G., Bunke, D., Fischer, P. Q., Salbaum, J. M., Masters, C. L., & Beyreuther, K. T. (1989) · Cell · doi:10.1016/0092-8674(89)90177-3 · Cited by 1,233 · see citing works

Enzyme changes in neonatal skeletal muscle: effect of thyroid deficiency

Baldwin, K. M., Hooker, A. M., Campbell, P., & Lewis, R. (1978) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1978.235.3.c97 · Cited by 1,118 · see citing works

Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine Receptors

Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898 · see citing works

Evidence that β-Amyloid Protein in Alzheimer's Disease Is Not Derived by Normal Processing

Sisodia, S. S., Koo, E. H., Beyreuther, K. T., Unterbeck, A., & Price, D. L. (1990) · Science · doi:10.1126/science.1691865 · Cited by 894 · see citing works

Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide

Haass, C., & Selkoe, D. J. (1993) · Cell · doi:10.1016/0092-8674(93)90312-e · Cited by 833 · see citing works

Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein

Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I. M., & Rydel, R. E. (1993) · Neuron · doi:10.1016/0896-6273(93)90315-i · Cited by 795 · see citing works

Activation of protein kinase C inhibits cellular production of the amyloid beta-protein.

Hung, A. Y., Haass, C., Nitsch, R. M., Qiu, W. Q., Citron, M., Wurtman, R. J., Growdon, J. H., & Selkoe, D. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49409-x · Cited by 399 · see citing works

Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

Shannon, H. E., Bymaster, F. P., Calligaro, D. O., Greenwood, B., Mitch, C. H., Sawyer, B. D., Ward, J. S., Wong, D. T., Olesen, P. H., & Sheardown, M. J. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38667-2 · Cited by 186 · see citing works

Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines

Sauerberg, P., Olesen, P. H., Nielsen, S., Treppendahl, S. P., Sheardown, M. J., Honoré, T., Mitch, C. H., Ward, J. S., & Pike, A. J. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00090a019 · Cited by 170 · see citing works

Phospholipase A2 Activation Influences the Processing and Secretion of the Amyloid Precursor Protein

Emmerling, M. R., Moore, C. J., Doyle, P. D., Carroll, R. T., & Davis, R. E. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2474 · Cited by 78 · see citing works

Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).

Bymaster, F. P., Wong, D. T., Mitch, C. H., Ward, J. S., Calligaro, D. O., Schoepp, D. D., Shannon, H. E., Sheardown, M. J., Olesen, P. H., & Suzdak, P. D. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38668-4 · Cited by 64 · see citing works

On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.

Forray, C., & El‐Fakahany, E. E. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11041-9 · Cited by 55 · see citing works

Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

Bodick, N. C., Offen, W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 687 · see citing works

Muscarinic acetylcholine receptors as CNS drug targets

Langmead, C. J., Watson, J. M., & Reavill, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.009 · Cited by 413 · see citing works

Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans

Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 370 · see citing works

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs

Perry, E. K., Kilford, L., Lees, A. J., Burn, D. J., & Perry, R. H. (2003) · Annals of Neurology · doi:10.1002/ana.10639 · Cited by 229 · see citing works

The Cholinergic Deficit Coincides with Aβ Deposition at the Earliest Histopathologic Stages of Alzheimer Disease

Beach, T. G., Kuo, Y., Spiegel, K., Emmerling, M. R., Sue, L. I., Kokjohn, K., & Roher, A. E. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.4.308 · Cited by 152 · see citing works

M1 Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy

Fisher, A., Pittel, Z., Haring, R., Bar-Ner, N., Kliger-Spatz, M., Natan, N., Egozi, I., Sonego, H., Marcovitch, I., & Brandeis, R. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:349 · Cited by 149 · see citing works

M1 muscarinic acetylcholine receptor in Alzheimer’s disease

Jiang, S., Li, Y., Zhang, C., Zhao, Y., Bu, G., Xu, H., & Zhang, Y. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1406-z · Cited by 147 · see citing works

Muscarinic receptor-mediated activation of nitric oxide synthase

Wotta, D. R., & El‐Fakahany, E. E. (1997) · Drug Development Research · doi:10.1002/(sici)1098-2299(199702)40:2 · Cited by 10 · see citing works

Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme

Schaeffer, E. L., & Gattaz, W. F. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1092-0 · Cited by 98 · see citing works

Therapeutic Strategies in Alzheimer’s Disease: Ml Muscarinic Agonists

Fisher, A. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.84.101 · Cited by 80 · see citing works

AF150(S) and AF267B

Fisher, A., Brandeis, R., Bar-Ner, R. H. N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0025-3 · Cited by 80 · see citing works

SCH 57790, a selective muscarinic M2 receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals

Carey, G. J., Billard, W., Binch, H., Cohen-Williams, M. E., Crosby, G., Grzelak, M. J., Guzik, H. S., Kozlowski, J. A., Lowe, D., Pond, A. J., et al. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01440-6 · Cited by 75 · see citing works

Septo-hippocampal cholinergic and neurotrophin markers in age-induced cognitive decline

Sugaya, K., Greene, R., Personett, D. A., Robbins, M., Kent, C., Bryan, D., Skiba, E., Gallagher, M., & McKinney, M. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00072-4 · Cited by 74 · see citing works

Potential Role of Muscarinic Agonists in Alzheimerʼs Disease

Avery, E., Baker, L. D., & Asthana, S. (1997) · Drugs & Aging · doi:10.2165/00002512-199711060-00004 · Cited by 71 · see citing works

Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists

Beach, T. G., Walker, D. G., Potter, P. E., Sue, L. I., & Fisher, A. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02484-2 · Cited by 66 · see citing works

Classics in Chemical Neuroscience: Xanomeline

Bender, A. M., Jones, C. K., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00001 · Cited by 65 · see citing works

Functional effects of the muscarinic receptor agonist, xanomeline, at 5‐HT1 and 5‐HT2 receptors

Watson, J. M., Brough, S., Coldwell, M. C., Gager, T., Ho, M., Hunter, A. J., Jerman, J. C., Middlemiss, D. N., Riley, G. J., & Brown, A. M. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702201 · Cited by 64 · see citing works

Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders

Digby, G. J., Shirey-Rice, J. K., & Conn, P. J. (2010) · Molecular BioSystems · doi:10.1039/c002938f · Cited by 62 · see citing works

Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects

Bymaster, F. P., Carter, P. A., Peters, S. C., Zhang, W., Ward, J. S., Mitch, C. H., Calligaro, D. O., Whitesitt, C. A., DeLapp, N. W., Shannon, H. E., et al. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00267-4 · Cited by 60 · see citing works

Pharmacologic treatment of cognition in Alzheimer's dementia

Farlow, M. R., & Evans, R. M. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s36 · Cited by 56 · see citing works

The Preclinical Pharmacological Profile of WAY-132983, a Potent M1 Preferring Agonist

Bartolomeo, A. C., Morris, H., Buccafusco, J. J., Kille, N. J., Rosenzweig-Lipson, S. J., Husbands, M., Sabb, A. L., Abou-Gharbia, M. A., Moyer, J. A., & Boast, C. A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35328-5 · Cited by 53 · see citing works

Therapeutic Potential of Multifunctional Tacrine Analogues

Przybyłowska, M., Kowalski, S., Dzierzbicka, K., & Inkielewicz‐Stępniak, I. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180412091908 · Cited by 49 · see citing works

Do cholinergic therapies have disease‐modifying effects in Alzheimer's disease?

Sabbagh, M. N., Farlow, M. R., Relkin, N. R., & Beach, T. G. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.02.001 · Cited by 48 · see citing works

Reduction of cortical amyloid β levels in guinea pig brain after systemic administration of physostigmine

Beach, T. G., Kuo, Y., Schwab, C., Walker, D. G., & Roher, A. E. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02076-6 · Cited by 40 · see citing works

Muscarinic Receptor Agonists in Alzheimer??s Disease

Fisher, A. (1999) · CNS Drugs · doi:10.2165/00023210-199912030-00004 · Cited by 37 · see citing works

Effects of the M1 Agonist Xanomeline on Processing of Human β-Amyloid Precursor Protein (FAD, Swedish Mutant) Transfected into Chinese Hamster Ovary-m1 Cells

DeLapp, N. W., Wu, S., Belagaje, R. M., Johnstone, E., Little, S., Shannon, H. E., Bymaster, F. P., Calligaro, D. O., Mitch, C. H., Whitesitt, C. A., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8235 · Cited by 29 · see citing works

Glutamate-stimulated secretion of amyloid precursor protein from cortical rat brain slices

Kirazov, L. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(96)00119-2 · Cited by 28 · see citing works

mRNA for the m4 muscarinic receptor subtype is expressed in adult rat brain cholinergic neurons

Sugaya, K., Clamp, C., Bryan, D., & McKinney, M. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00199-x · Cited by 28 · see citing works

Muscarinic agonists for the treatment of Alzheimer’s disease: progress and perspectives

Fisher, A. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.10.1395 · Cited by 27 · see citing works

Interaction of a new potent anticholinesterasic compound (±)huprine X with muscarinic receptors in rat brain

Roman, S. A., Vivas, N. M., Badı́a, A., & Clos, M. V. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00245-8 · Cited by 24 · see citing works

Strategies to identify natural antisense transcripts

Sun, Y., Li, D., Zhang, R., Shang, P., Zhang, G., Yang, T., & Qian, A. (2016) · Biochimie · doi:10.1016/j.biochi.2016.11.006 · Cited by 21 · see citing works

Impact of muscarinic agonists for successful therapy of Alzheimer’s disease

Fisher, A., Brandeis, R., Haring, R., Bar-Ner, N., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I., & Pittel, Z. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_18 · Cited by 19 · see citing works

Muscarinic M1receptor agonists and M2receptor antagonists as therapeutic targets in Alzheimer’s disease

Sheardown, M. J. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.6.863 · Cited by 18 · see citing works

Xanomeline Protects Cortical Cells From Oxygen-Glucose Deprivation via Inhibiting Oxidative Stress and Apoptosis

Xin, R., Chen, Z., Fu, J. X., Shen, F., Zhu, Q., & Huang, F. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00656 · Cited by 15 · see citing works

Development of CDD‐0102 as a selective M1 agonist for the treatment of Alzheimer's disease

Messer, W. S., Bachmann, K. A., Dockery, C. A., El‐Assadi, A. A., Hassoun, E. A., Haupt, N., Tang, B., & Li, X. (2002) · Drug Development Research · doi:10.1002/ddr.10153 · Cited by 12 · see citing works

Activation of Cerebral Function by CS-932, a Functionally Selective M1 Partial Agonist: Neurochemical Characterization and Pharmacological Studies

Iwata, N., Kozuka, M., Hara, T., Kaneko, T., Tonohiro, T., Sugimoto, M., Niitsu, Y., Kondo, Y., Yamamoto, T., Sakai, J., et al. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.84.266 · Cited by 11 · see citing works

Implications of Amyloid Precursor Protein and Subsequent β‐Amyloid Production to the Pharmacotherapy of Alzheimer's Disease

Rojas‐Fernandez, C. H., Chen, M., & Fernández, H. L. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.17.1547.34116 · Cited by 11 · see citing works

Effects of (±)-huprine Y and (±)-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors

Alcala, M. M., Maderuelo, A., Vivas, N. M., Camps, P., Muñoz‐Torrero, D., Clos, M. V., & Badı́a, A. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.12.044 · Cited by 9 · see citing works

Acylhydrazones as M1/M3 selective muscarinic agonists

Wu, E. S. C., Kover, A., Loch, J. T., Rosenberg, L., Semus, S. F., Verhoest, P. R., Gordon, J. C., Machulskis, A. C., McCreedy, S. A., Zongrone, J., et al. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00471-4 · Cited by 8 · see citing works

Development of a melatonin-based formulation for the treatment of insomnia in the elderly

Zisapel, N. (2000) · Drug Development Research · doi:10.1002/1098-2299(200007/08)50:3/4 · Cited by 16 · see citing works

Chapter 2 Alzheimer's Disease

DeKosky, S. T., & López, O. L. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70053-x · Cited by 5 · see citing works

Alkaloids

Wiart, C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398373-2.00001-7 · Cited by 4 · see citing works

Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?

Fodero, L. R., & Small, D. H. (2002) · Drug Development Research · doi:10.1002/ddr.10089 · Cited by 3 · see citing works

6β-Acetoxy nortropane regulated processing of amyloid precursor protein in CHOm1 cells and rat brain

Qiu, Y. L., Chen, H., Wu, X.-J., & Jin, Z.-J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01665-0 · Cited by 3 · see citing works

Anti‐amyloidogenic activity of cholinergic agents

Beach, T. G., Walker, D. G., Roher, A. E., & Potter, P. E. (2002) · Drug Development Research · doi:10.1002/ddr.10079 · Cited by 3 · see citing works

Muscarinic therapies in Alzheimer's disease; from palliative treatments to disease modification

Lovestone, S. (1997) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651509709069201 · Cited by 2 · see citing works

Cortical Cholinergic Lesion Causes Aβ Deposition: Cholinergic-Amyloid Fusion Hypothesis

Beach, T. G., Potter, P. E., Sue, L. I., Newell, A., Poston, M., Cisneros, R., Pandya, Y., Fisher, A., Roher, A. E., Lue, L., et al. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_44

Ansätze zur Frühbehandlung bei degenerativen Hirnerkrankungen

Herholz, K. (1998) · Springer eBooks · doi:10.1007/978-3-642-72204-2_23

Ml Muscarinic Agonists: From Treatment Toward Delaying Progression of Alzheimer’s Disease

Fisher, A., Haring, R., Pittel, Z., Eshhar, N., Karton, Y., Brandeis, R., Meshulam, H., Marciano, D., & Heldman, E. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_74

Beta-amyloids, tau hyperphosphorylation and cognition are beneficially affected by M1 muscarinic agonists

Pittel, Z., Haring, R., Bons, N., Bar-Ner, N., Sonego, H., Natan, N., Marcovitch, I., & Brandeis, R. (2004) · CRC Press eBooks · doi:10.3109/9780203493878-50

Neue Behandlungsansätze bei der Alzheimer-Demenz

Rösler, M., & Heidrich, A. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6400-6_70

BindingDB Entry 5193: Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.

BindingDB (2012) · UC San Diego · doi:10.7270/q2hm56zd

Novel M1 Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimer’s Disease

Fisher, A., Haring, R., Pittel, Z., Gurwitz, D., Karton, Y., Meshulam, H., Marciano, D., Brandeis, R., Heldman, E., Sadot, E., et al. (1997) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4116-4_47

Cortical Cholinergic Deafferentation Induces Aβ Deposition

Beach, T. G., Walker, D. G., Potter, P. E., Sue, L. I., Scott, S., Layne, K. J., Newell, A., Rauschkolb, P. K., Poston, M., Webster, S. D., et al. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-896-0_7

Effects of the M1 Agonist Xanomeline on Processing of Human β-Amyloid Precursor Protein (FAD, Swedish Mutant) Transfected into Chinese Hamster Ovary-m1 Cells

DeLapp, N. W., Wu, S., Belagaje, R. M., Johnstone, E., Little, S., Shannon, H. E., Bymaster, F. P., Calligaro, D. O., Mitch, C. H., Whitesitt, C. A., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8235 · Cited by 29 · see citing works

Muscarinic receptor-mediated activation of nitric oxide synthase

Wotta, D. R., & El‐Fakahany, E. E. (1997) · Drug Development Research · doi:10.1002/(sici)1098-2299(199702)40:2 · Cited by 10 · see citing works

Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects

Bymaster, F. P., Carter, P. A., Peters, S. C., Zhang, W., Ward, J. S., Mitch, C. H., Calligaro, D. O., Whitesitt, C. A., DeLapp, N. W., Shannon, H. E., et al. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00267-4 · Cited by 60 · see citing works

Pharmacological and clinical studies on M_1 muscarinic receptor agonist in treatment of Alzheimerdisease

Xing, W. (2003) · Zhongguo linchuang yaolixue yu zhiliaoxue · Cited by 2 · see citing works

Simultaneous changes in secretory amyloid precursor protein and β-amyloid peptide release from rat hippocampus by activation of muscarinic receptors

Qiu, Y. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)01007-3 · Cited by 1 · see citing works